Amicus Therapeutics Reports 22.1% Revenue Growth in Q2 2025, Net Loss Increases

Amicus Therapeutics, Inc. reported significant financial results for the second quarter of 2025, with net product sales reaching $154.7 million, a 22.1% increase from $126.7 million in the same period of 2024. For the first half of 2025, total net product sales amounted to $279.9 million, up from $237.1 million year-over-year. The company's gross profit for the quarter was $139.5 million, compared to $115.4 million in the prior year, reflecting a gross margin improvement driven by higher sales volumes. However, the company reported a net loss attributable to common stockholders of $24.4 million for the quarter, compared to a loss of $15.7 million in the same quarter of 2024.

The increase in revenue was primarily attributed to the continued growth of its flagship products, Galafold® and Pombiliti® + Opfolda®, in both the U.S. and European markets. Galafold® sales alone accounted for $128.9 million in the second quarter, while Pombiliti® + Opfolda® contributed $25.8 million. The company also noted a favorable impact of $5.3 million from foreign currency exchange rates. Operating expenses rose significantly, with research and development costs increasing to $60.8 million from $24.7 million, largely due to a $30 million upfront payment related to a licensing agreement with Dimerix for the commercialization of DMX-200, a drug candidate for Focal Segmental Glomerulosclerosis.

In terms of operational metrics, Amicus Therapeutics has expanded its employee headcount to support its growing product supply and development efforts. The company reported a total cash, cash equivalents, and marketable securities balance of $231 million as of June 30, 2025, which it believes is sufficient to fund operations and ongoing research programs for at least the next 12 months. The company is also actively pursuing geographic expansion and reimbursement agreements for its products in multiple countries.

Looking ahead, Amicus Therapeutics anticipates continued losses through the end of 2025 as it invests heavily in research and development and commercialization activities. The company is focused on advancing its pipeline, including the ongoing Phase 3 study of DMX-200, and is exploring additional business development opportunities to enhance its product offerings in the rare disease market. The management remains optimistic about the potential for future growth driven by its innovative therapies and strategic partnerships.